Structure-activity relationships of isoeugenol-based chlorophenylpiperazine derivatives on serotonergic/adrenergic receptor, platelet aggregation, and lipid peroxidation

Drug Development Research

Volumn 71, Issue 5, 2010, Pages 285-293

  Shen, Kuo Ping ^a   Chang, Wen Tsan ^b   Lin, Hui Li ^a   Chu, Li Wen ^c   Chen, Ing Jun ^c   Wu, Bin Nan ^c  

^a MEIHO UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adrenoceptor; Anti aggregation; Antioxidant; Serotonergic receptor

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 5 NONYLOXYTRYPTAMINE; ADRENALIN; ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ASCORBIC ACID; CLONIDINE; EUGENOSEDIN A; EUGENOSEDIN B; EUGENOSEDIN C; ISOEUGENOL; KETANSERIN; METHYSERGIDE; NORADRENALIN; SEROTONIN; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN RECEPTOR; TRYPTAMINE; UNCLASSIFIED DRUG; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG POTENCY; DRUG RECEPTOR BINDING; HEART RATE; HYPOTENSION; LIPID PEROXIDATION; MEAN ARTERIAL PRESSURE; NONHUMAN; RABBIT; RAT; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION; VASODILATATION;

EID: 77955988103     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20373     Document Type: Article

References (23)

1. Bylund DB, Blaxall HS, Murphy TJ. 1988. Alpha-2A and alpha-2B adrenergic receptor subtypes: antagonist binding in tissues and cell lines containing only one subtype. J Pharmacol Exp Ther 245:600-607.
2. 2A receptor. J Neurochem 63:465-469.
3. 3H]yohimbine and competitive inhibition by antidepressant drugs. Eur J Pharmacol 74:329-341.
4. Huang YC, Wu BN, Yeh JL, Chen SJ, Liang JC, Lo YC, Chen IJ. 2001. A new aspect of view in synthesizing new type beta-adrenoceptor blockers with ancillary antioxidant activities. Bioorg Med Chem 9:1739-1746.
5. Ishida T, Kawashima S, Hirata K, Sakoda T, Shimokawa Y, Miwa Y, Inoue N, Ueyama T, Shiomi M, Akita H, Yokoyama M. 2001. Serotonin-induced hypercontraction through 5-hydroxytryptamine 1B receptors in atherosclerotic rabbit coronary arteries. Circulation 103:1289-1295.
6. Krege S, Goepel M, Sperling H, Michel MC. 2000. Affinity of trazodone for human penile alpha1- and alpha2-adrenoceptors. BJU Int 85:959-961.
7. Le Roux MGJ, Syce JA. 1989. The effect of ketanserin on serotonin-induced vascular responses in the isolated perfused rat lung. Eur J Pharmacol 169:269-273.
8. Llado J, Esteban S, Garcia-Sevilla JA. 1996. The alpha 2-adrenoceptor antagonist idazoxan is an agonist at 5-HT1A autoreceptors modulating serotonin synthesis in the rat brain in vivo. Neurosci Lett 218:111-114.
9. McCloskey DJ, Postolache TT, Vittone BJ, Nghiem KL, Monsale JL, Wesley RA, Rick ME. 2008. Selective serotonin reuptake inhibitors: measurement of effect on platelet function. Transl Res 151:168-172.
10. 2-adrenoceptor inhibitor, binds to human platelets and inhibits their epinephrine-induced aggregation more effectively than yohimbine. Thromb Res 99:231-237.
11. O'Connor SE, Grosset A, Drieu La Rochelle C, Gautier E, Bidouard JP, Robineau P, Caille D, Janiak P. 2001. Cardiovascular effects of SL65.0472, a 5-HT receptor antagonist. Eur J Pharmacol 414:259-269. (Pubitemid 32181894)
12. Osborne NN, Wood JP. 2004. Metipranolol blunts nitric oxide-induced lipid peroxidation and death of retinal photoreceptors: a comparison with other anti-glaucoma drugs. Invest Ophthalmol Vis Sci 45:3787-3795.
13. Schultz BD, Singh AK, Devor DC, Bridges RJ. 1999. Pharmacology of CFTR Chloride Channel Activity. Physiol Rev 79:109-144.
14. Shen KP, Chiu CC, Chen SJ, Chen IJ, Wu BN. 2004. Hypotensive effects of eugenosedin-A with serotonin, alpha- and beta-adrenoceptor antagonistic activities in spontaneously hypertensive and normotensive rats. Pharmacology 71:91-101.
15. Shen KP, Lo YC, Yang RC, Liu HW, Chen IJ, Wu BN. 2005. Antioxidant eugenosedin-A protects against lipopolysaccharide- induced hypotension, hyperglycaemia and cytokine immunoreactivity in rats and mice. J Pharm Pharmacol 57:117-125.
16. Shen KP, Liou SF, Hsieh SL, Chen IJ, Wu BN. 2007. Eugenosedin-A amelioration of lipopolysaccharide-induced up-regulation of p38 MAPK, inducible nitric oxide synthase and cyclooxygenase-2. J Pharm Pharmacol 59:879-889. (Pubitemid 47051101)
17. Shen KP, Chu LW, Hsieh SL, An LM, Chen IJ, Wu BN. 2008. Hypotensive and antiaggregative effects of eugenosedin-B with serotonin and alpha/beta- adrenoceptor antagonistic activities in rats and human platelets. J Cardiovasc Pharmacol 51:154-161.
18. 2A "silent" receptors in rabbit ear artery. J Pharmacol Exp Ther 289:354-360.
19. Suehiro A, Marumo M, Yoshimoto H, Higasa S, Kakishita E. 1999. In vitro inhibitory effect of sarpogrelate hydrochloride on serotonin-induced platelet small-aggregate formation. Curr Ther Res 60:81-86.
20. Uma S, Kayaalp SO. 1987. The subtype of serotonin (5-HT) receptors in the rat pulmonary artery. Arch Int Pharmacodyn 288:248-255. (Pubitemid 17127968)
21. 2- adrenoceptors in the cardiovascular effects of monoxidine. Eur J Pharmacol 282:19-28.
22. Wu BN, Chen CF, Hong YR, Howng SL, Lin YL, Chen IJ. 2007. Activation of BKCa channels via cyclic AMP- and cyclic GMP-dependent protein kinases by eugenosedin-A in rat basilar artery myocytes. Br J Pharmacol 152:374-385.
23. 2 antagonist (SR46349). Thromb Res 81:555-567.